Mild cognitive impairment. Survey of attitudes of specialists and general physicians(865 views) Serrano CM, Allegri RF, Caramelli P, Taragano FE, Camera L
Keywords: Alzheimer, S Disease, Data Collection, Dementia, Mild Cognitive Impairment, Alpha Tocopherol, Cholinesterase Inhibitor, Memantine, Adult, Aged, Alzheimer Disease, Argentina, Article, Brazil, Cognitive Defect, Controlled Study, Disease Classification, Female, General Practitioner, Health Survey, Human, Medical Expert, Medical Specialist, Neurology, Physician Attitude, Psychiatrist, Questionnaire, Standardization, Treatment Planning, Aging, Attitude Of Health Personnel, Cognition Disorders, Vascular, Middle Aged, S Role, Professional Practice, Severity Of Illness Index,
Affiliations: *** IBB - CNR ***
Laboratorio de Investigación de la Memoria del Hospital A. Zubizarreta (GCBA), Buenos Aires, Argentina
Servicio de Neuropsicología (SIREN), Instituto Universitario CEMIC, Galván 4102, 1431 Buenos Aires, Argentina
Unidad de Neurologia Cognitiva y del Comportamiento, Sao Paulo, SP, Brazil
Programa de Medicina Geriátrica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
References: Not available.
Mild cognitive impairment. Survey of attitudes of specialists and general physicians
Mild cognitive impairment (MCI) refers to persons who are slightly cognitively impaired for age but do not meet the criteria for dementia. MCI has been related to a pre-dementia stage of Alzheimer's disease (AD). However, other possible diagnoses such as cerebro-vascular disease, frontotemporal dementia or normal aging have been considered. Diagnosis, etiology and conversion to dementia are a source of ambiguity in MCI. The aim was to evaluate the opinion of experts on dementia and of general practitioners concerning MCI. A total of 24 experts from Argentina and Brazil (16 neurologists and 8 psychiatrists) and 30 general practitioners agreed to reply to a questionnaire on MCI (adapted from Dubois inventory, 2003). Of these, 92% of experts considered MCI as an ambiguous entity, not necessarily as a "pre-dementia" stage; 63% confirmed a tendency to worsen over the time and 83% of experts decided to initiate treatment using cholinesterase inhibitors, memantine and vitamin E. The opinion on MCI was that a priori it is not only an Alzheimer disease pre-dementia stage, but most of them consider the treatment against AD. MCI is a heterogeneous entity that should be classified as an open category and making it necessary to standardize definitions and design diagnosis guides to better understand Alzheimer disease pre-dementia stage.
Mild cognitive impairment. Survey of attitudes of specialists and general physicians
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(1597 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote